Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?

References

• PerlrothJChoiBSpellbergBNosocomial fungal infections: epidemiology, diagnosis, and treatmentMed Mycol200745432134617510856
   PubMed Web of Science ®Google Scholar
• AlangadenGJNosocomial fungal infections: epidemiology, infection control, and preventionInfect Dis Clin North Am201125120122521316001
   PubMed Web of Science ®Google Scholar
• WHOOptions for ActionGenevaWHO Publication2012
   Google Scholar
• Sardi JdeCPitanguiNDSRodríguez-ArellanesGTaylorMLFusco-AlmeidaAMMendes-GianniniMJSHighlights in pathogenic fungal biofilmsRev Iberoam Micol2014311222924252828
   PubMed Web of Science ®Google Scholar
• PelgriftRYFriedmanAJNanotechnology as a therapeutic tool to combat microbial resistanceAdv Drug Deliv Rev20136513–141803181523892192
   PubMed Web of Science ®Google Scholar
• DorganEDenningDWMcMullanRBurden of fungal disease – IrelandJ Med Microbiol201564pt 442342625596121
   PubMedGoogle Scholar
• ChanderJStchigelAMAlastruey-IzquierdoAFungal necrotizing fasciitis, an emerging infectious disease caused by Apophysomyces (Mucorales)Rev Iberoam Micol2015322939825576377
   PubMedGoogle Scholar
• BrownGDDenningDWGowNALevitzSMNeteaMGWhiteTCHidden killers: human fungal infectionsSci Transl Med20124165165r v13
   Google Scholar
• BitarDLortholaryOLe StratYPopulation-based analysis of invasive fungal infections, France, 2001–2010Emerg Infect Dis20142071149115524960557
   PubMed Web of Science ®Google Scholar
• WHOAntimicrobial Resistance Global Report on Surveillance 2014GenevaWHO2014
   Google Scholar
• RuhnkeMAntifungal stewardship in invasive Candida infectionsClin Microbiol Infect201420suppl 6111824661820
   PubMed Web of Science ®Google Scholar
• VoltanARFusco-AlmeidaAMMendes–GianniniMJSCandiduria: epidemiology, resistance, classical and alternative antifungals drugsSOJ Microbiol Infect Dis20142217
   Google Scholar
• SchaalJVLeclercTSolerCEpidemiology of filamentous fungal infections in burned patients: a French retrospective studyBurns201541485386325681957
   PubMed Web of Science ®Google Scholar
• QuindósGEpidemiology of candidaemia and invasive candidiasis. A changing faceRev Iberoam Micol2014311424824270071
   PubMed Web of Science ®Google Scholar
• LinXHeitmanJThe biology of the Cryptococcus neoformans species complexAnnu Rev Microbiol2006606910516704346
   PubMed Web of Science ®Google Scholar
• ParkBJWannemuehlerKAMarstonBJGovenderNPappasPGChillerTMEstimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDSAIDS200923452553019182676
   PubMed Web of Science ®Google Scholar
• LinSJSchranzJTeutschSMAspergillosis case-fatality rate: systematic review of the literatureClin Infect Dis200132335836611170942
   PubMed Web of Science ®Google Scholar
• XieJLPolviEJShekhar-GuturjaTCowenLEElucidating drug resistance in human fungal pathogensFuture Microbiol20149452354224810351
   PubMed Web of Science ®Google Scholar
• ChenSCPlayfordEGSorrellTCAntifungal therapy in invasive fungal infectionsCurr Opin Pharmacol201010552253020598943
   PubMed Web of Science ®Google Scholar
• ChandrasekarPManagement of invasive fungal infections: a role for polyenesJ Antimicrob Chemother201166345746521172787
   PubMedGoogle Scholar
• PetrikkosGSkiadaARecent advances in antifungal chemotherapyInt J Antimicrob Agents200730210811717524625
   PubMed Web of Science ®Google Scholar
• AllenDWilsonDDrewRPerfectJAzole antifungals: 35 years of invasive fungal infection managementExpert Rev Anti Infect Ther201513678779825843556
   PubMed Web of Science ®Google Scholar
• AsciogluSChanKAUtilization and comparative effectiveness of caspofungin and voriconazole early after market approval in the U.SPLoS One201491e8365824427277
   PubMed Web of Science ®Google Scholar
• ChandwaniSWentworthCBurkeTAPattersonTFUtilization and dosage pattern of echinocandins for treatment of fungal infections in US hospital practiceCurr Med Res Opin200925238539319192983
   PubMed Web of Science ®Google Scholar
• McCormackPIsavuconazonium: first global approvalDrugs201575781782225902926
   PubMed Web of Science ®Google Scholar
• WeissigVPettingerTKMurdockNNanopharmaceuticals (part 1): products on the marketInt J Nanomedicine201494357437325258527
   PubMed Web of Science ®Google Scholar
• CalixtoGBernegossiJFonseca-SantosBChorilliMNanotechnology-based drug delivery systems for treatment of oral cancer: a reviewInt J Nanomedicine201493719373525143724
   PubMed Web of Science ®Google Scholar
• CouvreurPNanoparticles in drug delivery: past, present and futureAdv Drug Deliv Rev2013651212322580334
   PubMed Web of Science ®Google Scholar
• WilczewskaAZNiemirowiczKMarkiewiczKHCarHNanoparticles as drug delivery systemsPharmacol Rep2012641020103723238461
   PubMed Web of Science ®Google Scholar
• LiakosIGrumezescuAMHolbanAMMagnetite nanostructures as novel strategies for anti-infectious therapyMolecules2014198127101272625140449
   PubMedGoogle Scholar
• BaumgartnerJBertinettiLWiddratMHirtAMFaivreDFormation of magnetite nanoparticles at low temperature: from superparamagnetic to stable single domain particlesPLoS One201383e5707023520462
   PubMedGoogle Scholar
• AstrucDElectron-transfer processes in dendrimers and their implication in biology, catalysis, sensing and nanotechnologyNat Chem20124425526722437709
   PubMedGoogle Scholar
• Carrillo-MuñozAJQuindósGTurCIn-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazoleJ Antimicrob Chemother199944339740110511410
   PubMed Web of Science ®Google Scholar
• QuindósGCarrillo-MuñozAJRuesgaMTIn vitro activity of a new liposomal nystatin formulation against opportunistic fungal pathogensEur J Clin Microbiol Infect Dis200019864564811014634
   PubMedGoogle Scholar
• HamillRJAmphotericin B formulations: a comparative review of efficacy and toxicityDrugs201373991993423729001
   PubMed Web of Science ®Google Scholar
• CornelyOAAspergillus to zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infectionsInfection200836429631318642109
   PubMed Web of Science ®Google Scholar
• Laniado-LaborínRCabrales-VargasMNAmphotericin B: side effects and toxicityRev Iberoam Micol200926422322719836985
   PubMed Web of Science ®Google Scholar
• MoenMDLyseng-WilliamsonKAScottLJLiposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infectionsDrugs200969336139219275278
   PubMed Web of Science ®Google Scholar
• GómezJGarcía-VázquezEHernándezAEspinosaCRuizJNosocomial candidemia: new challenges of an emergent problemRev Esp Quimioter201023415816821191553
   PubMedGoogle Scholar
• WorkingPKAmphotericin B colloidal dispersion. Pre-clinical reviewChemotherapy199945suppl 1152610394017
   PubMedGoogle Scholar
• GrollAHMickieneDPiscitelliSCWalshTJDistribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbitsAntimicrob Agents Chemother200044240841010639371
   PubMedGoogle Scholar
• FieldingRMSingerAWWangLHBabbarSGuoLSRelationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogsAntimicrob Agents Chemother19923622993071605595
   PubMed Web of Science ®Google Scholar
• PatelRAmphotericin B colloidal dispersionExpert Opin Pharmacother20001347548811249532
   PubMedGoogle Scholar
• ArneyKLTiernanRJudsonMAPrimary pulmonary involvement of Fusarium solani in a lung transplant recipientChest19971124112811309377931
   PubMedGoogle Scholar
• QuindósGCarrillo-MuñozAJArévaloMPIn vitro susceptibility of Candida dubliniensis to current and new antifungal agentsChemotherapy200046639540111053905
   PubMed Web of Science ®Google Scholar
• SivakOBartlettKRisovicVAssessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with Caspofungin in experimental systemic aspergillosisJ Pharm Sci20049361382138915124198
   PubMed Web of Science ®Google Scholar
• PolacheckINaglerAOkonEDrakosPPlaskowitzJKwon-ChungKJAspergillus quadrilineatus, a new causative agent of fungal sinusitisJ Clin Microbiol19923012329032931452721
   PubMedGoogle Scholar
• DiamondDMBauerMDanielBEAmphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitisAntimicrob Agents Chemother19984235285339517927
   PubMedGoogle Scholar
• VidovicAArsic-ArsenijevicVTominDProven invasive pulmonary mucormycosis successfully treated with amphotericin B and surgery in patient with acute myeloblastic leukemia: a case reportJ Med Case Rep2013726324299522
   PubMedGoogle Scholar
• DietzeRFowlerVGSteinerTSPecanhaPMCoreyGRFailure of amphotericin B colloidal dispersion in the treatment of paracoccidioidomycosisAm J Trop Med Hyg199960583783910344661
   PubMed Web of Science ®Google Scholar
• HansonLHStevensDAComparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersionAntimicrob Agents Chemother19923624864881605618
   PubMed Web of Science ®Google Scholar
• TimmersGJZweegmanSSimoons-SmitAMvan LoenenACTouwDHuijgensPCAmphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trialBone Marrow Transplant200025887988410808210
   PubMed Web of Science ®Google Scholar
• VogelsingerHWeilerSDjananiAAmphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersionJ Antimicrob Chemother20065761153116016627591
   PubMed Web of Science ®Google Scholar
• RuijgrokEJFensMHABakker-WoudenbergIAJMvan EttenEWMVultoAGNebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: evidence for long-term biological activityJ Pharm Pharmacol200557101289129516259757
   PubMedGoogle Scholar
• HusainSCapitanoBCorcoranTIntrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipientsTransplantation201090111215121920881664
   PubMed Web of Science ®Google Scholar
• YangWTamJMillerDAHigh bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizersInt J Pharm20083611–217718818556158
   PubMedGoogle Scholar
• HostetlerJSClemonsKVHansonLHStevensDAEfficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosisAntimicrob Agents Chemother19923612265626601482133
   PubMed Web of Science ®Google Scholar
• TkatchLSKusneSEiblingDSuccessful treatment of zygomycosis of the paranasal sinuses with surgical debridement and amphotericin B colloidal dispersionAm J Otolaryngol19931442492538214317
   PubMedGoogle Scholar
• VukmirRBKusneSLindenPSuccessful therapy for cerebral phaeohyphomycosis due to Dactylaria gallopava in a liver transplant recipientClin Infect Dis19941947147197803637
   PubMedGoogle Scholar
• HerbrechtRLetscher-BruVBowdenRATreatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersionEur J Clin Microbiol Infect Dis200120746046611561801
   PubMed Web of Science ®Google Scholar
• NoskinGAPietrelliLCoffeyGGurwithMLiangLJAmphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patientsClin Infect Dis19982624614679502471
   PubMedGoogle Scholar
• MosesAERahavGBarenholzYRhinocerebral mucormycosis treated with amphotericin B colloidal dispersion in three patientsClin Infect Dis1998266143014339636875
   PubMed Web of Science ®Google Scholar
• HunstadDACohenAHSt GemeJWSuccessful eradication of mucormycosis occurring in a pulmonary allograftJ Heart Lung Transplant199918880180410512529
   PubMed Web of Science ®Google Scholar
• BowdenRChandrasekarPWhiteMHA double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patientsClin Infect Dis200235435936612145716
   PubMed Web of Science ®Google Scholar
• CapillaJClemonsKVSobelRAStevensDAEfficacy of amphotericin B lipid complex in a rabbit model of coccidioidal meningitisJ Antimicrob Chemother200760367367617646202
   PubMedGoogle Scholar
• WeilerSUberlacherESchofmannJPharmacokinetics of amphotericin B colloidal dispersion in critically ill patients with cholestatic liver diseaseAntimicrob Agents Chemother201256105414541822850517
   PubMedGoogle Scholar
• SunHYCacciarelliTVSinghNMicafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipientsTransplantation201396657357823842191
   PubMedGoogle Scholar
• MadniASarfrazMRehmanMAhmadMAkhtarNAhmadSLiposomal drug delivery: a versatile platform for challenging clinical applicationsJ Pharm Pharm Sci201417340142625224351
   PubMed Web of Science ®Google Scholar
• DaiYZhouRLiuLLuYQiJWuWLiposomes containing bile salts as novel ocular delivery systems for tacrolimus (FK506): in vitro characterization and improved corneal permeationInt J Nanomedicine201381921193323690687
   PubMed Web of Science ®Google Scholar
• CorcoranTEVenkataramananRMihelcKMAerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipientsAm J Transplant20066112765277317049064
   PubMedGoogle Scholar
• HatakeyamaHAkitaHHarashimaHThe polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumorsBiol Pharm Bull201336689289923727912
   PubMed Web of Science ®Google Scholar
• AhmadIAllenTMAntibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitroCancer Res19925217481748201511445
   PubMedGoogle Scholar
• JooKIXiaoLLiuSCrosslinked multilamellar liposomes for controlled delivery of anticancer drugsBiomaterials201334123098310923375392
   PubMed Web of Science ®Google Scholar
• IbrahimASAvanessianVSpellbergBEdwardsJELiposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzaeAntimicrob Agents Chemother200347103343334414506054
   PubMed Web of Science ®Google Scholar
• OrtonedaMCapillaJPastorFJPujolIGuarroJEfficacy of liposomal amphotericin B in treatment of systemic murine fusariosisAntimicrob Agents Chemother20024672273227512069988
   PubMed Web of Science ®Google Scholar
• OlsonJAAdler-MooreJPJensenGMSchwartzJDignaniMCProffittRTComparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B productsAntimicrob Agents Chemother200852125926817967910
   PubMed Web of Science ®Google Scholar
• SloanDJParrisVCryptococcal meningitis: epidemiology and therapeutic optionsClin Epidemiol2014616918224872723
   PubMed Web of Science ®Google Scholar
• ClemonsKVSobelRAWilliamsPLPappagianisDStevensDAEfficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbitsAntimicrob Agents Chemother20024682420242612121913
   PubMedGoogle Scholar
• ClemonsKVCapillaJSobelRAMartinezMTongAJStevensDAComparative efficacies of lipid-complexed amphotericin B and liposomal amphotericin B against coccidioidal meningitis in rabbitsAntimicrob Agents Chemother20095351858186219273680
   PubMedGoogle Scholar
• ClemonsKVStevensDATherapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosisJ Antimicrob Chemother19933234654728262869
   PubMed Web of Science ®Google Scholar
• OlsonJAAdler-MooreJPSchwartzJJensenGMProffittRTComparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis modelAntimicrob Agents Chemother20065062122213116723574
   PubMed Web of Science ®Google Scholar
• Al NakeebZPetraitisVGoodwinJPetraitieneRWalshTJHopeWWPharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex and liposomal amphotericin B against Aspergillus fumigatusAntimicrob Agents Chemother20155952735274525712363
   PubMedGoogle Scholar
• ArianoREMitchelmoreBRLagacé-WiensPRZelenitskySASuccessful treatment of pulmonary blastomycosis with continuously infused amphotericin B deoxycholate after failure with liposomal amphotericin BAnn Pharmacother2013476e2623673538
   PubMed Web of Science ®Google Scholar
• Akyol ErikciAOzyurtMTerekeciHOzturkAKarabudakOOncuKOesophageal aspergillosis in a case of acute lymphoblastic leukaemia successfully treated with caspofungin alone due to liposomal amphotericin B induced severe hepatotoxicityMycoses2009521848618498301
   PubMedGoogle Scholar
• SatoMRda SilvaPBde SouzaRAdos SantosKCChorilliMRecent advances in nanoparticle carriers for coordination complexesCurr Top Med Chem201515428729725579344
   PubMed Web of Science ®Google Scholar
• LiuJSChangYYChenWHChenSSAmphotericin B-induced leukoencephalopathy in a patient with cryptococcal meningitisJ Formos Med Assoc19959474324347549570
   PubMed Web of Science ®Google Scholar
• MichotJMGubavuCFournEVery prolonged liposomal amphotericin B use leading to a lysosomal storage diseaseInt J Antimicrob Agents201443656656924787480
   PubMedGoogle Scholar
• HospenthalDRRogersALMillsGLDevelopment of amphotericin B liposomes bearing antibody specific to Candida albicansMycopathologia1988101137453281020
   PubMed Web of Science ®Google Scholar
• GilbertBEWydePRWilsonSZAerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in miceAntimicrob Agents Chemother1992367146614711510442
   PubMedGoogle Scholar
• MiharaTKakeyaHIzumikawaKEfficacy of aerosolized liposomal amphotericin B against murine invasive pulmonary mucormycosisJ Infect Chemother201420210410824462443
   PubMedGoogle Scholar
• Alonso-VargasRGonzález-AlvarezLRuesgaMTIn vitro activity of a liposomal nystatin formulation (Nyotran) against Cryptococcus neoformansRev Iberoam Micol2000173909215762799
   PubMedGoogle Scholar
• OakleyKLMooreCBDenningDWComparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazoleAntimicrob Agents Chemother19994351264126610223948
   PubMed Web of Science ®Google Scholar
• Lopez-BeresteinGBodeyGPFrankelLSMehtaKTreatment of hepatosplenic candidiasis with liposomal-amphotericin BJ Clin Oncol1987523103173806172
   PubMed Web of Science ®Google Scholar
• SchinabeckMKLongLAHossainMARabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapyAntimicrob Agents Chemother20044851727173215105127
   PubMed Web of Science ®Google Scholar
• SeidlerMSalvenmoserSMüllerFMLiposomal amphotericin B eradicates Candida albicans biofilm in a continuous catheter flow modelFEMS Yeast Res201010449249520345899
   PubMedGoogle Scholar
• RamageGJoseASherryLLappinDFJonesBWilliamsCLiposomal amphotericin B displays rapid dose-dependent activity against Candida albicans biofilmsAntimicrob Agents Chemother20135752369237123422915
   PubMed Web of Science ®Google Scholar
• DrewRPotential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infectionsInt J Antimicrob Agents200627suppl 1364416713192
   PubMed Web of Science ®Google Scholar
• RothCGebhartJJust-NublingGvon Eisenhart-RotheBBeinhauer-ReebICharacterization of amphotericin B aerosols for inhalation treatment of pulmonary aspergillosisInfection19962453543608923045
   PubMed Web of Science ®Google Scholar
• GilbertBEWydePRLopez-BeresteinGWilsonSZAerosolized amphotericin B-liposomes for treatment of systemic Candida infections in miceAntimicrob Agents Chemother19943823563598192464
   PubMedGoogle Scholar
• Lopez-BeresteinGMehtaRHopferRMehtaKHershEMJulianoREffects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasisCancer Drug Deliv19831137426544116
   PubMedGoogle Scholar
• Lopez-BeresteinGFainsteinVHopferRLiposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary studyJ Infect Dis198515147047103973417
   PubMed Web of Science ®Google Scholar
• WeberRSLopez-BeresteinGTreatment of invasive Aspergillus sinusitis with liposomal-amphotericin BLaryngoscope1987978 pt 19379413613794
   PubMedGoogle Scholar
• PontaniDRSunDBrownJWInhibition of HIV replication by liposomal encapsulated amphotericin BAntiviral Res19891131191252472114
   PubMedGoogle Scholar
• KatzNMPiercePFAnzeckRALiposomal amphotericin B for treatment of pulmonary aspergillosis in a heart transplant patientJ Heart Transplant19909114172313415
   PubMedGoogle Scholar
• TollemarJDurajFEriczonBGLiposomal amphotericin B treatment in a 9-month-old liver recipientMycoses19903352512522267002
   PubMedGoogle Scholar
• AntunesAMTeixeiraCCorvoMLPerdigotoRBarrosoEMarcelinoPProphylactic use of liposomal amphotericin B in preventing fungal infections early after liver transplantation: a retrospective, single-center studyTransplant Proc201446103554355925498088
   PubMed Web of Science ®Google Scholar
• SelleslagDA case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin BActa Biomed200677suppl 2323516918066
   PubMedGoogle Scholar
• FisherEWTomaAFisherPHCheesmanADRhinocerebral mucormycosis: use of liposomal amphotericin BJ Laryngol Otol199110575755771875144
   PubMedGoogle Scholar
• LimKKPottsMJWarnockDWIbrahimNBBrownEMBurns-CoxCJAnother case report of rhinocerebral mucormycosis treated with liposomal amphotericin B and surgeryClin Infect Dis19941846536548038329
   PubMedGoogle Scholar
• OgawaTTakezawaKTojimaISuccessful treatment of rhino-orbital mucormycosis by a new combination therapy with liposomal amphotericin B and micafunginAuris Nasus Larynx201239222422821592699
   PubMedGoogle Scholar
• MunckhofWJonesRTosoliniFAMarzecAAngusPGraysonMLCure of Rhizopus sinusitis in a liver transplant recipient with liposomal amphotericin BClin Infect Dis19931611838448307
   PubMed Web of Science ®Google Scholar
• CokerRJVivianiMGazzardBGTreatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDSAIDS1993768298358363759
   PubMed Web of Science ®Google Scholar
• KaratzaAADimitriouGMarangosMSuccessful resolution of cardiac mycetomas by combined liposomal Amphotericin B with Fluconazole treatment in premature neonatesEur J Pediatr200816791021102318205013
   PubMedGoogle Scholar
• TungerOBayramHDegerliKDincGCetinBCComparison of the efficacy of combination and monotherapy with caspofungin and liposomal amphotericin B against invasive candidiasisSaudi Med J200829572873318454223
   PubMedGoogle Scholar
• BucklerBSSamsRNGoeiVLTreatment of central venous catheter fungal infection using liposomal amphotericin-B lock therapyPediatr Infect Dis J200827876276418664989
   PubMed Web of Science ®Google Scholar
• KashimotoSTakemotoKYamamotoYKanazawaKIn vivo activity of liposomal amphotericin B against Exophiala dermatitidis in a murine lethal infection modelJpn J Antibiot201063326527220976882
   PubMedGoogle Scholar
• Ruíz-CendoyaMPastorFJCapillaJGuarroJTreatment of murine Fusarium verticillioides infection with liposomal amphotericin B plus terbinafineInt J Antimicrob Agents2011371586120947310
   PubMedGoogle Scholar
• InoueAHaradaHIwataSIntraventricular cryptococcoma successfully treated with liposomal amphotericin B and voriconazole: a case reportNo Shinkei Geka201240977778422915699
   PubMedGoogle Scholar
• SharmaLCFalodiaJKallaKEsophageal histoplasmosis in a renal allograft recipientSaudi J Kidney Dis Transpl201324476476723816727
   PubMedGoogle Scholar
• BrazzolaPRossiMRHigh weekly doses of liposomal amphotericin B as secondary prophylaxis after cerebral aspergillosis in a paediatric patientMed Mycol Case Rep2013311324567890
   PubMedGoogle Scholar
• VilleSTalarminJPGaultier-LintiaADisseminated mucormycosis with cerebral involvement owing to rhizopus microsporus in a kidney recipient treated with combined liposomal amphotericin b and posaconazole therapyExp Clin Transpl20161419699
   Google Scholar
• KleinotieneGPosiunasGRaistenskisJLiposomal amphotericin B and surgery as successful therapy for pulmonary Lichtheimia corymbifera zygomycosis in a pediatric patient with acute promyelocytic leukemia on antifungal prophylaxis with posaconazoleMed Oncol201330143323307250
   PubMedGoogle Scholar
• HandEORamanathanMRSafety and tolerability of high-dose weekly liposomal amphotericin B antifungal prophylaxisPediatr Infect Dis J201433883583625222303
   PubMedGoogle Scholar
• StormLLauschKRArendrupMCMortensenKLPetersenEVertebral infection with Candida albicans failing caspofungin and fluconazole combination therapy but successfully treated with high dose liposomal amphotericin B and flucytosineMed Mycol Case Rep201466925379389
   PubMedGoogle Scholar
• RousseauNPicotSBBienvenuALErythropoietin combined with liposomal amphotericin B improves outcome during disseminated aspergillosis in miceFront Immunol2014550225352847
   PubMedGoogle Scholar
• FujitaMYanagisawaJHiratsukaMA case report of pulmonary aspergillosis in lung transplant recipient successfully treated with inhalation administration of liposomal amphotericin BJpn J Antibiot2013661374323777015
   PubMedGoogle Scholar
• GodetCGoudetVLaurentFNebulised liposomal amphotericin B for Aspergillus lung diseases: case series and literature reviewMycoses201558317318025690951
   PubMed Web of Science ®Google Scholar
• HanadaSUrugaHTakayaHNebulized liposomal amphotericin B for treating Aspergillus empyema with bronchopleural fistulaAm J Respir Crit Care Med2014189560760824579838
   PubMedGoogle Scholar
• SouzaACNascimentoALde VasconcelosNMActivity and in vivo tracking of amphotericin B loaded PLGA nanoparticlesEur J Med Chem20159526727625827397
   PubMed Web of Science ®Google Scholar
• MukherjeeSRaySThakurRSDesign and evaluation of Itraconazole loaded solid lipid nanoparticulate system for improving the antifungal therapyPak J Pharm Sci200922213113819339221
   PubMedGoogle Scholar
• PardeshiCRajputPBelgamwarVSolid lipid based nanocarriers: an overviewActa Pharm201262443347223333884
   PubMed Web of Science ®Google Scholar
• NayakAPTiyaboonchaiWPatankarSMadhusudhanBSoutoEBCurcuminoids-loaded lipid nanoparticles: novel approach towards malaria treatmentColloids Surf B Biointerfaces201081126327320688493
   PubMed Web of Science ®Google Scholar
• MuchowMMaincentPMullerRHLipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug deliveryDrug Dev Ind Pharm200834121394140518665980
   PubMed Web of Science ®Google Scholar
• Abdel-MottalebMMANeumannDLamprechtALipid nanocapsules for dermal application: a comparative study of lipid-based versus polymer-based nanocarriersEur J Pharm Biopharm2011791364221558002
   PubMed Web of Science ®Google Scholar
• AttamaAASchickeBCPaepenmüllerTMüller-GoymannCCSolid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterizationEur J Pharm Biopharm2007671485717276663
   PubMed Web of Science ®Google Scholar
• LiuJGongTFuHSolid lipid nanoparticles for pulmonary delivery of insulinInt J Pharm20083561–233334418281169
   PubMed Web of Science ®Google Scholar
• SznitowskaMGajewskaMJanickiSRadwanskaALukowskiGBioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbitsEur J Pharm Biopharm200152215916311522481
   PubMed Web of Science ®Google Scholar
• MüllerRHRadtkeMWissingSASolid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparationsAdv Drug Deliv Rev200254suppl 1S131S15512460720
   PubMed Web of Science ®Google Scholar
• ZhangLChanJMGuFXSelf-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platformACS Nano2008281696170219206374
   PubMed Web of Science ®Google Scholar
• Salvador-MoralesCZhangLLangerRFarokhzadOCImmunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groupsBiomaterials200930122231224019167749
   PubMed Web of Science ®Google Scholar
• MüllerRHRungeSARavelliVThünemannAFMehnertWSoutoEBCyclosporine-loaded solid lipid nanoparticles (SLN®): drug-lipid physicochemical interactions and characterization of drug incorporationEur J Pharm Biopharm200868353554417804210
   PubMed Web of Science ®Google Scholar
• TanSWBillaNRobertsCRBurleyJCSurfactant effects on the physical characteristics of Amphotericin B-containing nanostructured lipid carriersColloids Surf A Physicochem Eng Asp20103721–37379
   Web of Science ®Google Scholar
• KovacevicASavicSVuletaGMüllerRHKeckCMPolyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structureInt J Pharm20114061–216317221219990
   PubMedGoogle Scholar
• MathpalDGargTRathGGoyalAKDevelopment and characterization of spray dried microparticles for pulmonary delivery of antifungal drugCurr Drug Deliv201512446447125808185
   PubMedGoogle Scholar
• MohantyBMajumdarDKMishraSKPandaAKPatnaikSDevelopment and characterization of itraconazole-loaded solid lipid nanoparticles for ocular deliveryPharm Dev Technol201520445846424490828
   PubMed Web of Science ®Google Scholar
• PardeikeJWeberSHaberTDevelopment of an Itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary applicationInt J Pharm20114191–232933821839157
   PubMed Web of Science ®Google Scholar
• LimWMRajinikanthPSMallikarjunCKangYBFormulation and delivery of itraconazole to the brain using a nanolipid carrier systemInt J Nanomedicine201492117212624833900
   PubMed Web of Science ®Google Scholar
• SanapGSMohantaGPDesign and evaluation of miconazole nitrate loaded nanostructured lipid carriers (NLC) for improving the antifungal therapyJ Appl Pharm Sci2013314654
   Google Scholar
• KeshriLPathakKDevelopment of thermodynamically stable nanostructured lipid carrier system using central composite design for zero order permeation of Econazole nitrate through epidermisPharm Dev Technol2012183111
   Google Scholar
• SongSHLeeKMKangJBLeeSGKangMJChoiYWImproved skin delivery of voriconazole with a nanostructured lipid carrier-based hydrogel formulationChem Pharm Bull (Tokyo)201462879379825087631
   PubMed Web of Science ®Google Scholar
• LemkeAKiderlenAFKayserOAmphotericin BAppl Microbiol Biotechnol200568215116215821914
   PubMed Web of Science ®Google Scholar
• JainSJainSKharePGulbakeABansalDJainSKDesign and development of solid lipid nanoparticles for topical delivery of an anti-fungal agentDrug Deliv201017644345120486871
   PubMed Web of Science ®Google Scholar
• GuptaMVyasSPDevelopment, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasisChem Phys Lipids2012165445446122309657
   PubMed Web of Science ®Google Scholar
• RavaniLEspositoEBoriesCClotrimazole-loaded nanostructured lipid carrier hydrogels: thermal analysis and in vitro studiesInt J Pharm2013454269570223792467
   PubMed Web of Science ®Google Scholar
• MendesAISilvaACCatitaJAMCerqueiraFGabrielCLopesCMMiconazole-loaded nanostructured lipid carriers (NLC) for local delivery to the oral mucosa: improving antifungal activityColloids Surf B Biointerfaces201311175576323954816
   PubMed Web of Science ®Google Scholar
• GuptaMTiwariSVyasSPInfluence of various lipid core on characteristics of SLNs designed for topical delivery of fluconazole against cutaneous candidiasisPharm Dev Technol201318355055921810069
   PubMed Web of Science ®Google Scholar
• VaghasiyaHKumarASawantKDevelopment of solid lipid nanoparticles based controlled release system for topical delivery of terbinafine hydrochlorideEur J Pharm Sci201349231132223557842
   PubMed Web of Science ®Google Scholar
• CassanoRFerrarelliTMauroMVCavalcantiPPicciNTrombinoSPreparation, characterization and in vitro activities evaluation of solid lipid nanoparticles based on PEG-40 stearate for antifungal drugs vaginal deliveryDrug Deliv20162331047105625005582
   PubMedGoogle Scholar
• MeloSCunhaSFialhoSLFormas farmacêuticas poliméricas para a administração de peptídeos e proteínas terapêuticos [Polymeric delivery systems for the administration of therapeutic peptides and proteins]Rev Ciênc Farm Básica Apl2012334469477 Portuguese
   Google Scholar
• PridgenEMAlexisFFarokhzadOCPolymeric nanoparticle technologies for oral drug deliveryClin Gastroenterol Hepatol201412101605161024981782
   PubMed Web of Science ®Google Scholar
• ValenciaPMPridgenEMRheeMLangerRFarokhzadOCKarnikRMicrofluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapyACS Nano2013712106711068024215426
   PubMed Web of Science ®Google Scholar
• YuMKParkJJonSTargeting strategies for multifunctional nanoparticles in cancer imaging and therapyTheranostics20122134422272217
   PubMed Web of Science ®Google Scholar
• des RieuxAFievezVGarinotMSchneiderYJPréatVNanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approachJ Controll Release20061161127
   PubMed Web of Science ®Google Scholar
• BilensoyESarisozenCEsendaǧliGIntravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumorsInt J Pharm20093711–217017619135514
   PubMed Web of Science ®Google Scholar
• BaiJLiYDuJOne-pot synthesis of polyacrylamide-gold nanocompositeMater Chem Phys20071062–3412415
   Google Scholar
• TurosEShimJYWangYAntibiotic-conjugated polyacrylate nanoparticles: new opportunities for development of anti-MRSA agentsBioorg Med Chem Lett2007171535617049850
   PubMed Web of Science ®Google Scholar
• MaoHQRoyKTroung-LeVLChitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiencyJ Control Release200170339942111182210
   PubMed Web of Science ®Google Scholar
• RejinoldNSMuthunarayananMMuthuchelianKChennazhiKPNairSVJayakumarRSaponin-loaded chitosan nanoparticles and their cytotoxicity to cancer cell lines in vitroCarbohydr Polym2011841407416
   Web of Science ®Google Scholar
• GonçalvesJODuarteDADPlaaGLUse of chitosan with different deacetylation degrees for the adsorption of food dyes in a binary systemClean Soil Air Water2014426767774
   Google Scholar
• SaraogiGKGuptaPGuptaUDJainNKAgrawalGPGelatin nanocarriers as potential vectors for effective management of tuberculosisInt J Pharm20103851–214314919819315
   PubMed Web of Science ®Google Scholar
• LuoGYuXJinCLyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumorsInt J Pharm20103851–215015619825404
   PubMed Web of Science ®Google Scholar
• Mora-HuertasCEFessiHElaissariAPolymer-based nanocapsules for drug deliveryInt J Pharm20103851–211314219825408
   PubMed Web of Science ®Google Scholar
• SchaffazickSRGuterresSSDe Lucca FreitasLPohlmannARCaracterização e estabilidade físico-química de sistemas poliméricos nanoparticulados para administração de fármacos. [Physicochemical characterization and stability of the polymeric nanoparticle systems for drug administration]Quim Nova2003265726737 Portuguese
   Web of Science ®Google Scholar
• AnselmoACMitragotriSA review of clinical translation of inorganic nanoparticlesAAPS J20151751041105425956384
   PubMed Web of Science ®Google Scholar
• PintoRJBAlmeidaAFernandesSCMAntifungal activity of transparent nanocomposite thin films of pullulan and silver against Aspergillus nigerColloids Surf B Biointerfaces201310314314823201731
   PubMedGoogle Scholar
• SilvaSPiresPMonteiroDRThe effect of silver nanoparticles and nystatin on mixed biofilms of Candida glabrata and Candida albicans on acrylicMed Mycol201351217818422803822
   PubMed Web of Science ®Google Scholar
• MonteiroDRNegriMSilvaSAdhesion of Candida biofilm cells to human epithelial cells and polystyrene after treatment with silver nanoparticlesColloids Surf B Biointerfaces201411441041224257686
   PubMedGoogle Scholar
• MehnertWMaderKSolid lipid nanoparticles – production, characterization and applicationsAdv Drug Deliv Rev2001472–316519611311991
   PubMed Web of Science ®Google Scholar
• VakilRKnilansKAndesDKwonGSCombination antifungal therapy involving amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micellesPharm Res20082592056206418415047
   PubMedGoogle Scholar
• WangCHWangWTHsiueGHDevelopment of polyion complex micelles for encapsulating and delivering amphotericin BBiomaterials200930193352335819299011
   PubMed Web of Science ®Google Scholar
• AmaralACMarquesAFMuñozJEPoly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosisBr J Pharmacol201015951126113220136827
   PubMedGoogle Scholar
• XuNGuJZhuYWenHRenQChenJEfficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in miceInt J Nanomedicine2011690591321720503
   PubMed Web of Science ®Google Scholar
• PatelNRDamannKLeonardiCSabliovCSize dependency of PLGA-nanoparticle uptake and antifungal activity against Aspergillus flavusNanomedicine (Lond)2011681381139521651442
   PubMed Web of Science ®Google Scholar
• Cunha-AzevedoEPSilvaJRMartinsOPIn vitro antifungal activity and toxicity of itraconazole in DMSA-PLGA nanoparticlesJ Nanosci Nanotechnol20111132308231421449386
   PubMed Web of Science ®Google Scholar
• Roy ChoudhurySGhoshMMandalASurface-modified sulfur nanoparticles: an effective antifungal agent against Aspergillus niger and Fusarium oxysporumAppl Microbiol Biotechnol201190273374321350853
   PubMedGoogle Scholar
• ShimYHKimYCLeeHJAmphotericin b aggregation inhibition with novel nanoparticles prepared with poly(ε-caprolactone)/poly(N,N-dimethylamino-2-ethyl methacrylate) diblock copolymerJ Microbiol Biotechnol2011211283621301189
   PubMedGoogle Scholar
• HaghighiFMohammadiShRMohammadiPEskandariMHosseinkhaniSThe evaluation of Candida albicans biofilms formation on silicone catheter, PVC and glass coated with titanium dioxide nanoparticles by XTT method and ATPase assayBratisl Lek List201211312707711
   Google Scholar
• ShaoKWuJChenZA brain-vectored angiopep-2 based polymeric micelles for the treatment of intracranial fungal infectionBiomaterials201233286898690722789719
   PubMed Web of Science ®Google Scholar
• Van De VenHPaulussenCFeijensPBPLGA nanoparticles and nanosuspensions with amphotericin B: potent in vitro and in vivo alternatives to Fungizone and AmBisomeJ Control Release2012161379580322641062
   PubMed Web of Science ®Google Scholar
• MohammedNSanoj RejinoldNMangalathillamSBiswasRNairSVJayakumarRFluconazole loaded chitin nanogels as a topical ocular drug delivery agent for corneal fungal infectionsJ Biomed Nanotechnol2013991521153123980500
   PubMedGoogle Scholar
• MathewTVKuriakoseSPhotochemical and antimicrobial properties of silver nanoparticle-encapsulated chitosan functionalized with photoactive groupsMater Sci Eng C201333744094415
   Google Scholar
• SantosSSLorenzoniAFerreiraLMClotrimazole-loaded Eudragit® RS100 nanocapsules: preparation, characterization and in vitro evaluation of antifungal activity against Candida speciesMater Sci Eng C Mater Biol Appl20133331389139423827586
   PubMed Web of Science ®Google Scholar
• BashaMAbd El-AlimSHShammaRNAwadGEDesign and optimization of surfactant-based nanovesicles for ocular delivery of ClotrimazoleJ Liposome Res201323320321023607316
   PubMed Web of Science ®Google Scholar
• SantosSSLorenzoniAPegoraroNSFormulation and in vitro evaluation of coconut oil-core cationic nanocapsules intended for vaginal delivery of clotrimazoleColloids Surf B Biointerfaces201411627027624503350
   PubMed Web of Science ®Google Scholar
• AzevedoMMRamalhoPSilvaAPTeixeira-SantosRPina-VazCRodriguesAGPolyethyleneimine and polyethyleneimine-based nanoparticles: novel bacterial and yeast biofilm inhibitorsJ Med Microbiol201463pt 91167117324913563
   PubMedGoogle Scholar
• LazniewskaJMilowskaKGabryelakTDendrimers-revolutionary drugs for infectious diseasesWiley Interdiscip Rev Nanomed Nanobiotechnol20124546949122761054
   PubMed Web of Science ®Google Scholar
• WuLFickerMChristensenJBTrohopoulosPNMoghimiSMDendrimers in medicine: therapeutic concepts and pharmaceutical challengesBioconjug Chem20152671198121125654320
   PubMed Web of Science ®Google Scholar
• D’EmanueleAAttwoodDDendrimer-drug interactionsAdv Drug Deliv Rev200557152147216216310283
   PubMed Web of Science ®Google Scholar
• MenjogeARKannanRMTomaliaDADendrimer-based drug and imaging conjugates: design considerations for nanomedical applicationsDrug Discov Today2010155–617118520116448
   PubMed Web of Science ®Google Scholar
• GajbhiyeVVijayaraj KumarPKumar TekadeRJainNKPharmaceutical and biomedical potential of pegylated dendrimersCurr Pharm Design200713415429
   Web of Science ®Google Scholar
• ZiembaBJanaszewskaACiepluchKIn vivo toxicity of poly(propyleneimine) dendrimersJ Biomed Mater Res A201199226126821976451
   PubMedGoogle Scholar
• KolhatkarRBKitchensKMSwaanPWGhandehariHSurface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeabilityBioconjug Chem20071862054206017960872
   PubMed Web of Science ®Google Scholar
• SinghPGuptaUAsthanaAJainNKFolate and Folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing miceBioconjug Chem200819112239225218950215
   PubMed Web of Science ®Google Scholar
• WänglerCMoldenhauerGEisenhutMHaberkornUMierWAntibody-dendrimer conjugates: the number, not the size of the dendrimers, determines the immunoreactivityBioconjug Chem200819481382018361514
   PubMedGoogle Scholar
• WaiteCLRothCMPAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant gliomaBioconjug Chem200920101908191619775120
   PubMed Web of Science ®Google Scholar
• LopezAIReinsRYMcDermottAMTrautnerBWCaiCAntibacterial activity and cytotoxicity of PEGylated poly(amidoamine) dendrimersMol Biosyst20095101148115619756304
   PubMedGoogle Scholar
• WinnickaKSosnowskaKWieczorekPSachaPTTryniszewskaEPoly(amidoamine) dendrimers increase antifungal activity of ClotrimazoleBiol Pharm Bull20113471129113321720026
   PubMed Web of Science ®Google Scholar
• JaniszewskaJSowińskaMRajniszANovel dendrimeric lipopeptides with antifungal activityBioorg Med Chem Lett20122231388139322230049
   PubMedGoogle Scholar
• StaniszewskaMBondarykMZielinskaPUrbańczyk-LipkowskaZThe in vitro effects of new D186 dendrimer on virulence factors of Candida albicansJ Antibiot (Tokyo)201467642543224690909
   PubMedGoogle Scholar
• BenincasaMPacorSWuWPratoMBiancoAGennaroRAnti-fungal activity of amphotericin B conjugated to carbon nanotubesACS Nano20115119920821141979
   PubMedGoogle Scholar
• OliviMZanniEDe BellisGInhibition of microbial growth by carbon nanotube networksNanoscale20135199023902923934344
   PubMedGoogle Scholar
• SawangphrukMSrimukPChiochanPSangsriTSiwayaprahmPSynthesis and antifungal activity of reduced graphene oxide nanosheetsCarbon N Y2012501451565161
   Google Scholar
• CuiJYangYZhengMFacile fabrication of graphene oxide loaded with silver nanoparticles as antifungal materialsMater Res Express20141445007
   Google Scholar
• Hussein-Al-AliSHEl ZowalatyMEHusseinMZGeilichBMWebsterTJSynthesis, characterization, and antimicrobial activity of an ampicillin-conjugated magnetic nanoantibiotic for medical applicationsInt J Nanomedicine2014913801381425143729
   PubMedGoogle Scholar
• NiemirowiczKSwiecickaIWilczewskaAZGrowth arrest and rapid capture of select pathogens following magnetic nanoparticle treatmentColloids Surf B Biointerfaces2015131293825942700
   PubMed Web of Science ®Google Scholar
• RoemerTKrysanDJAntifungal drug development: challenges, unmet clinical needs, and new approachesCold Spring Harb Perspect Med201445 pii a019703
   PubMed Web of Science ®Google Scholar
• OyafusoMHCarvalhoFCChiavacciLAGremiãoMPDChorilliMDesign and characterization of silicone and surfactant based systems for topical drug deliveryJ Nanosci Nanotechnol201515181782626328446
   PubMed Web of Science ®Google Scholar
• LiuXChenXLiYWangXPengXZhuWPreparation of superparamagnetic Fe 3O 4@alginate/chitosan nanospheres for candida rugosa lipase immobilization and utilization of layer-by-layer assembly to enhance the stability of immobilized lipaseACS Appl Mater Interfaces20124105169517822985256
   PubMed Web of Science ®Google Scholar